ICP | Innovators Commercialisation Program

The ICP – Innovators Commercialisation Program is led by Asia Research & Innovation Alliance (ARIA)’s Institute of Healthtech Excellence, in collaboration with the National University Hospital of Singapore (NUHS) – Centre for Innovation in Healthcare (CIH). ICP program helps innovators to accelerate their product validation and expansion into Singapore.

A global team of healthcare professionals and clinicians will offer clinical validation and venture building support to grow your business in Singapore and the region over a 6 months program. Completion of the ICP program will allow innovators access to venture investment of up to USD1,000,000.

BENEFITS OF THE PROGRAM
– Venture Funding of $1million Dollars
– Establish Global HQ in Singapore with Regulatory Incentives
– Fast Track to Clinical Adoption and Trials in Singapore and across Asia
– Network with the largest Medtech companies in the world
– Access to a Global Committee of Medical Industry Professionals

PROGRAM THEMES
1. Improving Users Lifespans and Quality of Life
2. Enabling Seamless Delivery of High-Quality Healthcare
3. Digitalisation of Hospital Systems
4. Enhancing Women’s and Children’s Health Outcomes

PROGRAM STRUCTURE
The program is split into 3 phases of 6 months in total:
1. Phase 1 covers the Clinical Validation phase with the NUHS-CIH team, with access to 3 major hospitals and 8 polyclinics in Singapore.
2. Phase 2 is the product actuation process with the venture building team comprising of top medical industry professionals.
3. Phase 3 is the venture funding and scale-up process, with key support provided in operational roles

SELECTION CRITERIA
1. Prototypes have been developed
2. Patents approved or pending approval
3. Obtained preliminary clinical trial data and/or published in research publications
4. Business plans developed

HOW DO YOU APPLY?
Send your 1 slide business plan to [email protected] OR apply through the website https://www.ariainstitute.org/icp

Company’s Keywords: